Invest in 10,000+ US Stocks and ETFs
* Offering through VF Securities, Inc. (member FINRA/SIPC)
PureTech Health plc, engages in the development and commercialization of biotechnology and pharmaceutical solutions in the United States. The company is developing LYT-100, which is under Phase 2 stage, to treat idiopathic pulmonary fibrosis (IPF); and LYT-200, a IgG4 monoclonal antibody, currently under Phase 1/2 stage, targeting galectin-9 for treating solid tumors and hematological malignancies. It also develops SPT-300, an oral drug of allopregnanolone for the treatment of anxious depression; SPT-320, a novel prodrug of agomelatine for the treatment of generalized anxiety disorder; and SPT-348, a prodrug of a non-hallucinogenic neuroplastogen for the treatment of mood and other neuropsychiatric disorders. In addition, the company is developing hydrogels to enable the oral administration of peptide therapeutics in preclinical development. The company was incorporated in 2015 and is headquartered in Boston, Massachusetts. more
Time Frame | PRTC | Sector | S&P500 |
---|---|---|---|
1-Week Return | -3.35% | -3.39% | 0.2% |
1-Month Return | 1.16% | -1.92% | 2.72% |
3-Month Return | 11.26% | -10.54% | 7.31% |
6-Month Return | -24.28% | -4.47% | 10.44% |
1-Year Return | 15.4% | 4.06% | 27.53% |
3-Year Return | -47.04% | 0.94% | 30.88% |
5-Year Return | -43.38% | 36.67% | 89.21% |
Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | 5YR TREND | |
---|---|---|---|---|---|---|
Total Revenue | 8.69M | 8.34M | 9.98M | 2.09M | 3.33M | [{"date":"2019-12-31","value":87.06,"profit":true},{"date":"2020-12-31","value":83.59,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":20.94,"profit":true},{"date":"2023-12-31","value":33.37,"profit":true}] |
Cost of Revenue | - | - | 110.47M | 152.43M | 4.93M | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":72.47,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":3.24,"profit":true}] |
Gross Profit | 8.69M | 8.34M | (100.49M) | (150.34M) | (1.60M) | [{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":96.01,"profit":true},{"date":"2021-12-31","value":-1156.68,"profit":false},{"date":"2022-12-31","value":-1730.47,"profit":false},{"date":"2023-12-31","value":-18.45,"profit":false}] |
Gross Margin | 100.00% | 100.00% | (1007.03%) | (7193.44%) | (48.14%) | [{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":-1007.03,"profit":false},{"date":"2022-12-31","value":-7193.44,"profit":false},{"date":"2023-12-31","value":-48.14,"profit":false}] |
Operating Expenses | 144.09M | 127.87M | 160.26M | 199.90M | 146.95M | [{"date":"2019-12-31","value":72.08,"profit":true},{"date":"2020-12-31","value":63.97,"profit":true},{"date":"2021-12-31","value":80.17,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":73.51,"profit":true}] |
Operating Income | (135.40M) | (119.53M) | (150.28M) | (197.81M) | (146.20M) | [{"date":"2019-12-31","value":-13539900000,"profit":false},{"date":"2020-12-31","value":-11953100000,"profit":false},{"date":"2021-12-31","value":-15028200000,"profit":false},{"date":"2022-12-31","value":-19780700000,"profit":false},{"date":"2023-12-31","value":-14619900000,"profit":false}] |
Total Non-Operating Income/Expense | 579.55M | 136.74M | 86.83M | 106.87M | 112.62M | [{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":23.59,"profit":true},{"date":"2021-12-31","value":14.98,"profit":true},{"date":"2022-12-31","value":18.44,"profit":true},{"date":"2023-12-31","value":19.43,"profit":true}] |
Pre-Tax Income | 478.47M | 18.97M | (58.95M) | (92.78M) | (36.10M) | [{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":3.96,"profit":true},{"date":"2021-12-31","value":-12.32,"profit":false},{"date":"2022-12-31","value":-19.39,"profit":false},{"date":"2023-12-31","value":-7.55,"profit":false}] |
Income Taxes | 112.41M | 14.40M | 3.76M | (55.72M) | 30.52M | [{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":12.81,"profit":true},{"date":"2021-12-31","value":3.34,"profit":true},{"date":"2022-12-31","value":-49.57,"profit":false},{"date":"2023-12-31","value":27.16,"profit":true}] |
Income After Taxes | 366.06M | 4.57M | (62.71M) | (37.06M) | (66.63M) | [{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":1.25,"profit":true},{"date":"2021-12-31","value":-17.13,"profit":false},{"date":"2022-12-31","value":-10.12,"profit":false},{"date":"2023-12-31","value":-18.2,"profit":false}] |
Income From Continuous Operations | 366.06M | 4.57M | (62.71M) | (37.06M) | (66.63M) | [{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":1.25,"profit":true},{"date":"2021-12-31","value":-17.13,"profit":false},{"date":"2022-12-31","value":-10.13,"profit":false},{"date":"2023-12-31","value":-18.2,"profit":false}] |
Income From Discontinued Operations | - | - | - | - | - | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Net Income | 421.14M | 4.57M | (62.71M) | (37.06M) | (65.70M) | [{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":1.08,"profit":true},{"date":"2021-12-31","value":-14.89,"profit":false},{"date":"2022-12-31","value":-8.8,"profit":false},{"date":"2023-12-31","value":-15.6,"profit":false}] |
EPS (Diluted) | 1.50 | 1.47 | - | - | - | [{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":98.05,"profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
These ratios help you determine the liquidity of the company. Higher is better.
PRTC | |
---|---|
Cash Ratio | 3.62 |
Current Ratio | 3.68 |
Quick Ratio | 2.30 |
These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.
PRTC | |
---|---|
ROA (LTM) | -13.39% |
ROE (LTM) | -22.07% |
These ratios help you understand the company's liabilities, gauging the riskiness of the investment.
PRTC | |
---|---|
Debt Ratio Lower is generally better. Negative is bad. | 0.47 |
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. | 0.54 |
These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.
PRTC | |
---|---|
Trailing PE | NM |
Forward PE | NM |
P/S (TTM) | 1115.25 |
P/B | 1.65 |
Price/FCF | NM |
EV/R | 348.82 |
EV/Ebitda | NM |
PureTech Health PLC (PRTC) share price today is $21.2
Yes, Indians can buy shares of PureTech Health PLC (PRTC) on Vested. To buy PureTech Health PLC from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in PRTC stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.
Yes, you can purchase fractional shares of PureTech Health PLC (PRTC) via the Vested app. You can start investing in PureTech Health PLC (PRTC) with a minimum investment of $1.
You can invest in shares of PureTech Health PLC (PRTC) via Vested in three simple steps:
The 52-week high price of PureTech Health PLC (PRTC) is $34. The 52-week low price of PureTech Health PLC (PRTC) is $19.02.
The price-to-earnings (P/E) ratio of PureTech Health PLC (PRTC) is
The price-to-book (P/B) ratio of PureTech Health PLC (PRTC) is 1.65
The dividend yield of PureTech Health PLC (PRTC) is 0.00%
The market capitalization of PureTech Health PLC (PRTC) is $521.94M
The stock symbol (or ticker) of PureTech Health PLC is PRTC